CD3/BCMA/CD38 Trispecific Antibodies

The present invention relates to novel trispecific heterodimeric immunoglobulins. More specifically the present invention relates to trispecific heterodimeric immunoglobulins that target human CD3 antigen, human BCMA and human CD38 antigen. The present invention also relates to this novel class of t...

Full description

Saved in:
Bibliographic Details
Main Authors MACOIN, Julie, CHIMEN, Myriam, LOYAU, Jérémy, MONNEY, Thierry, DREYFUS, Cyrille, PIHLGREN BOSCH, Maria, CROASDALE-WOOD, Rebecca, PERRO, Mario, SRIVASTAVA, Ankita, DYSON, Michael, CARRETERO IGLESIA, Laura, PAIS, Daniela, ESTOPPEY, Carole, HALL, Olivia, DRAKE, Adam
Format Patent
LanguageEnglish
Published 25.04.2024
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to novel trispecific heterodimeric immunoglobulins. More specifically the present invention relates to trispecific heterodimeric immunoglobulins that target human CD3 antigen, human BCMA and human CD38 antigen. The present invention also relates to this novel class of trispecific heterodimeric immunoglobulins for use in the treatment of proliferative diseases and in particular cancers such as hematological cancer. The present invention relates to novel trispecific antibody for use in treating multiple myeloma.
Bibliography:Application Number: US202318312519